Clinical trial · Interventional
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
A Phase I/II Trial of Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT for Inoperable,Locally Advanced Esophageal Carcinoma
NCT02762474CI-TRIAL-00025844unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is going to evaluate the efficacy and safety of IMRT / nab-TP chemotherapy for unresectable esophageal cancer, and to investigate the optimal concurrent chemotherapy regimen for local advanced and unresectable esophageal cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nab-paclitaxel group | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nab-paclitaxel group
- description
- Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
- interventionNames
- Drug: nab-paclitaxel group
Primary outcomes (1)
- measure
- Progress free survival
- timeFrame
- 3 years
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 3 years
- measure
- CTCAE 4.0 toxicity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. inoperable locally advanced histologically confirmed esophageal cancer (T3N0M0-TxNxM1a（AJCC 2002) 2. ECOG performance status scale 0-1 3. at least 1 measurable target lesions 4. white blood count ≥ 3,500/mm3, absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 100,000/mm3, hemoglobin count ≥ 90 g/dL, serum bilirubin level \< 1.5 of the upper limit of normal (ULN) for the institution, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase ≤ 2.5 ULN, serum albumin ≥ 30g/L, serum creatinine ≤ 1.5 ULN; and 5. normal cardiac function with no severe heart disease. Exclusion Criteria: 1. history of esophagectomy 2. pregnancy or breast feeding 3. past history of other cancers except for cured non-melanoma skin cancer or cervical cancer; 4. concomitant treatment with other anticancer drugs.
References
Publications (0)
Data not yet available
No reference posted for this study.